SymposiaReg - The Official Registration site for Voxmedia Symposia

Sign up today for the following Symposium:

Management Of Arrhythmias In Patients With Ischemic Heart Disease

This program is not part of the Heart Rhythm 2008 Official Scientific Sessions as planned by the Heart Rhythm Society Scientific Sessions Committee. This event is neither sponsored nor endorsed by the Heart Rhythm Society.

Faculty: Jeremy N. Ruskin, M.D.(Chair); Peter R. Kowey, M.D.

Topic:

In this symposium, current management of arrhythmias in patients with ischemic heart disease will be reviewed, with emphasis on benefit/risk to the patient, and unmet needs for development of new therapies. In addition, recent data with new pharmacologic approaches will be described, with discussion about their potential utility in patients with ischemic heart disease and different types of arrhythmia.

Event Date: Thursday, May 15, 2008
Venue Address: Hilton San Fransisco Union Square, 333 O'Farrell Street, San Francisco, CA
Room: Grand Ballroom A - Tower 2
Registration Start Time: 6:00AM
Program Start/End Times: 6:30AM - 7:45AM

* At the conclusion of the symposium, the first 100 attendees submitting a CME evaluation will receive a free USB flash drive.

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Voxmedia gratefully acknowledges the educational grant provided by: CV Therapeutics, Inc.

Pre-Registration

	First Name:
	Last Name:
	Degree:
	Title:
	Specialty:
	Affiliation:
	Address 1:
	Address 2:
	City:
	State:
	Province:
	Zip Code:
	Country:
	Address Type:	Home Office
	Phone:
	Fax:
	Email:

	Pre-Meeting Survey
	1. True or False. Vernakalant has the electrophysiologic properties of a multiple ion channel blocker. True False
	2. True or False. In experimental models, ranolazine produces potent use-dependent depression of sodium channel current and related parameters in the atria and ventricle, leading to effective suppression of AF. True False
	3. In patients with ventricular tachyarrhythmias who do not meet criteria for an ICD, ______ is/are first-line therapy. Amiodarone. Sotalol. Beta blockers. All of the above.
	4. True or False . Inhibition of the ultrarapid delayed rectified potassium current selectively prolongs atrial repolarization and can suppress AF. True False
	5. Etiologies and factors predisposing patients to AF include: Drugs. Atrial ischemia. Endocrine disorders. A and B only. All of the above.

		Please check here if you would be willing to participate in a pre-meeting and post-meeting survey.
		Please contact me when future programming becomes available.